
399 - The evolution of Alzheimer's disease and dementia care | Gayatri Devi, M.D.
Summary: The Evolution of Alzheimer's Disease and Dementia Care – A Conversation with Dr. Gayatri Devi
In this episode of The Drive Podcast, Peter Attia speaks with neurologist and psychiatrist Dr. Gayatri Devi about the evolution of Alzheimer's and dementia care. Dr. Devi shares her decades of experience and a revolutionary, personalized approach.
Key Takeaways:- Dementia is a spectrum, not a binary disease: Alzheimer's, vascular dementia, and Lewy body dementia often overlap. Pathology (amyloid plaques, tau tangles, neuroinflammation) varies greatly between individuals.
- Early detection is crucial: High-functioning patients compensate for a long time—therefore, extensive testing (cognitive assessments, EEG, transcranial Doppler, MRI, amyloid/tau PET, spinal tap) is needed to spot early changes.
- Biomarkers and blood test limitations: Blood-based biomarkers (e.g., Aβ42/40) are promising but not diagnostic alone. Amyloid plaques also occur in healthy older adults; an Alzheimer diagnosis should include clinical symptoms and tau pathology.
- New antibody therapies: Lecanemab and donanemab remove amyloid, but clinical benefit is modest. Risks: brain edema and microbleeds (ARIA). Dr. Devi uses a slow dose escalation to minimize side effects, especially in APOE4 carriers.
- Personalized combination therapy: Similar to HIV, tailored "cocktails" are used: cholinesterase inhibitors, memantine, anti-inflammatory strategies, transcranial magnetic stimulation (TMS), and targeted brain exercises.
- Neuroinflammation as a new target: Viruses (herpes simplex, varicella-zoster) and chronic inflammation (e.g., from periodontitis) may trigger Alzheimer's. Vaccinations (e.g., against shingles) have been shown to reduce risk.
- Sex differences: Women have a higher Alzheimer's risk, partly due to estrogen decline during menopause. Dr. Devi coined the term "menopause-related cognitive impairment" (Mercy) and treats it with hormone replacement, cognitive exercises, and TMS.
- APOE4 gene: Two copies massively increase risk. However, some carriers may remain protected by a strong immune system or other factors.
- Lewy body dementia: Often confused with Parkinson's. Characteristic: visual hallucinations with preserved insight, no resting tremor. Treatment differs fundamentally (no dopamine agonists).
- Future visions: Artificial intelligence for early detection, targeted immune modulation, and personalized drug cocktails will revolutionize dementia care.
Alzheimer's is not a hopeless diagnosis. With early, individualized diagnosis and therapy, many patients can remain stable or even improve. The key lies in combining modern antibodies, lifestyle interventions, and combating inflammation.






